BRIEF published on 10/26/2026 at 11:05, 1 day 18 hours ago AL-S Pharma Unveils Promising Phase 2 Results and Phase 3 Plans for AP-101 in ALS Phase 3 Trial ALS AP-101 AL-S Pharma Weight Preservation
BRIEF published on 10/26/2026 at 11:05, 1 day 18 hours ago AL-S Pharma dévoile des résultats prometteurs de phase 2 et ses plans pour la phase 3 de l'AP-101 dans la SLA Essai De Phase 3 SLA AP-101 Pharmacie AL-S Préservation Du Poids
PRESS RELEASE published on 10/26/2026 at 11:00, 1 day 18 hours ago AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual Meeting
BRIEF published on 10/14/2026 at 08:05, 13 days 21 hours ago AL-S Pharma Appoints Harry Welten as CEO Clinical Trials Financial Strategy ALS Treatment Biotech Leadership Harry Welten
BRIEF published on 10/14/2026 at 08:05, 13 days 21 hours ago AL-S Pharma nomme Harry Welten au poste de PDG Stratégie Financière Essais Cliniques Traitement De La SLA Leadership En Biotechnologie Harry Welten
PRESS RELEASE published on 10/14/2026 at 08:00, 13 days 21 hours ago AL-S Pharma Appoints Harry Welten as Chief Executive Officer AL-S Pharma appoints Harry Welten as Chief Executive Officer to lead AP-101 into confirmatory Phase 3 trial. Mr. Welten brings over 25 years of CFO and chairman experience in life sciences industry Biotechnology CEO Phase 3 Trial AL-S Pharma Harry Welten
BRIEF published on 06/24/2026 at 17:25, 4 months 3 days ago AL-S Pharma Reports Positive AP-101 Phase 2 Findings for ALS Treatment Clinical Trial ALS Treatment Phase 2 Data SOD1 Misfolding AP-101 Antibody
BRIEF published on 06/24/2026 at 17:25, 4 months 3 days ago AL-S Pharma annonce des résultats positifs pour l'étude de phase 2 de l'AP-101 dans le traitement de la SLA. Essai Clinique Traitement De La SLA Données De La Phase 2 Repliement Incorrect De SOD1 Anticorps AP-101
PRESS RELEASE published on 06/24/2026 at 17:20, 4 months 3 days ago AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026 AL-S Pharma presents Phase 2 data on AP-101 supporting misfolded SOD1 as ALS therapeutic target at ENCALS 2026. Key study results and clinical implications discussed ALS Phase 2 Data SOD1 AL-S Pharma ENCALS 2026
BRIEF published on 03/19/2026 at 07:35, 7 months 8 days ago AL-S Pharma's AP-101 Shows Promise in ALS Treatment Clinical Trial ALS Treatment Phase 2 Data AP-101 SOD1 Targeting
Published on 10/28/2026 at 02:55, 2 hours 31 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 2 hours 36 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 5 hours 46 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 6 hours 1 minute ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/27/2026 at 21:30, 7 hours 56 minutes ago Apex Announces Closing of Over-Allotment Option
Published on 10/28/2026 at 02:25, 3 hours 1 minute ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 AGM Chair and Group CEO address
Published on 10/28/2026 at 02:19, 3 hours 7 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: September 2026 quarter update
Published on 10/27/2026 at 22:40, 6 hours 45 minutes ago EQS-Adhoc: NEXTDC Limited: Financial Covenants - Compliance and Headroom
Published on 10/27/2026 at 22:30, 6 hours 56 minutes ago Tensor and Münchner Taxi Zentrum Sign LOI to Put Taxi Operators at the Center of Autonomous Mobility in Germany
Published on 10/27/2026 at 20:35, 8 hours 51 minutes ago Piramal Pharma Limited Announces Results for Q2 and H1 FY27
Published on 10/27/2026 at 18:00, 11 hours 26 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 11 hours 26 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
